GlassScriptPhysician profile
Edward L Sames
NPI 1508855123
$1,148.45
in general payments reported to CMS, 2019-2025
23 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $89.68 · 2023: $194 · 2024: $458 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,058.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $170.59 | 2022-2025 | |
| Novo Nordisk INC | $165.72 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $153.09 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.62 | 2024-2025 | Caplyta |
| Abbott Laboratories | $82.99 | 2023-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre |
| Abbvie INC. | $63.42 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.10 | 2024-2025 | Trintellix |
| Exact Sciences Corporation | $44.06 | 2024-2025 | Cologuard Collection Kit |
| Abiomed | $33.91 | 2025 | |
| Boston Scientific Corporation | $32.78 | 2024 | |
| Amgen INC. | $32.47 | 2023-2024 | Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $31.44 | 2024-2025 | Voquezna |
| Medtronic, INC. | $24.57 | 2025 | Minimed 780g |
| Regeneron Healthcare Solutions, INC. | $22.75 | 2024 | Evkeeza |
| Axsome Therapeutics, INC. | $19.80 | 2024 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avvisto Therapeutics, LLC | $18.42 | 2025 | Cycloset |
| Corcept Therapeutics | $16.77 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $14.90 | 2024 | Inspire |
| Glaxosmithkline, LLC. | $14.73 | 2023 | Shingrix |
| Astellas Pharma US INC | $14.46 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $14.08 | 2022 | |
| Merck Sharp & Dohme LLC | $13.97 | 2023 | Verquvo, Belsomra |
| Dynavax Technologies Corporation | $13.81 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Sames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.